Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $32 from $22 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results but they believe the cmmpany has promising potential but some related risk including increasing competition, and price elasticity of demand issues.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics announces Atera, a new in situ spatial biology platform
- 10x Genomics price target raised to $30 from $22 at Barclays
- 10x Genomics price target raised to $24 from $18 at Citi
- 10x Genomics upgraded to Outperform from Market Perform at William Blair
- Is Cathie Wood Turning Bearish on Bullish (BLSH) Stock?